Effect of Metadoxine on Oxidative Stress in Non-alcoholic Hepatic Steatosis

Phase 4

• Conditions: NAFLD; Pre-diabetes
• Interventions: Drug: Metadoxine

• Registration Number: NCT02051842
• Lead Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Brief Summary

Oxidative stress is produced by imbalance between reactive oxygen species and antioxidant systems. This state is frequently associated with chronic diseases like obesity, insulin resistance, metabolic syndrome and hepatic steatosis. In the liver, the oxidative stress may trigger the progression of fatty liver disease, from triglyceride accumulation to inflammation, cirrhosis and hepatocellular carcinoma. Thus, the attenuation of oxidative stress, could be an important therapeutic target to lessen the severity of the disease. Until now, there is not a medical treatment to cure non-alcoholic fatty liver disease, but therapies aimed at reducing oxidative stress have been proposed. Metadoxine, an ionic complex of pyridoxine-pyrrolidone molecule, acts as a synthetic antioxidant, forming traps that can reduce free radicals; likewise, metadoxine has a proven capacity to reduce fat liver in alcoholic hepatitis. Finally, in fact that alcoholic and non-alcoholic liver diseases share molecular mechanisms in the generation of oxidative stress, the investigators propose metadoxine as a posssible modifier of the oxidative stress in non-alcoholic liver disease, prediabetic patients.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2014-01-30
• Study First Submitted QC: 2014-01-30
• Study First Posted: 2014-01-31
• Study Start: 2016-01
• Status Verified: 2019-01
• Last Update Submitted: 2019-01-29
• Last Update Posted: 2019-01-31
• Primary Completion: 2020-01
• Study Completion: 2020-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Male and female
• 18 to 65 years old
• Ultrasonographic diagnosis of NAFLD
• Prediabetes diagnosis

Exclusion Criteria

• Alcoholism
• Hepatitis C or B Virus Infection
• Pregnancy
• Autoimmune hepatitis
• Metformin or metadoxine allergy
• Parenteral nutrition in the last month
• Weigh loss greater than 10% in the last month
• Taking vitamin supplements in the last month

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Metadoxine	Metadoxine	Metadoxine 500 mg tablets by mouth every 12 hours for 6 months and metformin 500 mg tablets by mouth every 8 hours for 6 months
Placebo tablet	Metadoxine	Placebo tablet (for Metadoxine) by mouth every 12 hours for 6 months and metformin 500 mg tablets by mouth every 8 hours for 6 months

Primary Outcome Measures

Name	Time	Method
Oxidative stress	Baseline	Malondialdehyde levels

Trial Locations

Locations (1)

Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán"; 🇲🇽 Mexico City, Mexico